AIM ImmunoTech Inc. (AIM) stock
AIMNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.13−0.01 (-3.75%)
Close on Nov 18, 2026Market cap $3.98MP/E –Yield –
AIM ImmunoTech free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
AIM ImmunoTech's free cash flow for the twelve months ending Dec 31, 2024 was -$14.91M. For fiscal 2024 it was -$14.91M. The highest annual figure on record is -$7.54M in fiscal 2016.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -$14.91M | – |
| FY2022 | Dec 31, 2022 | -$16.19M | – |
| FY2021 | Dec 31, 2021 | -$14.01M | – |
| FY2020 | Dec 31, 2020 | -$10.39M | – |
| FY2019 | Dec 31, 2019 | -$9.14M | – |
| FY2018 | Dec 31, 2018 | -$10.69M | – |
| FY2017 | Dec 31, 2017 | -$7.96M | – |
| FY2016 | Dec 31, 2016 | -$7.54M | – |
| FY2015 | Dec 31, 2015 | -$16.29M | – |
| FY2014 | Dec 31, 2014 | -$14.47M | – |
| FY2013 | Dec 31, 2013 | -$17.80M | – |
| FY2012 | Dec 31, 2012 | -$18.89M | – |
| FY2011 | Dec 31, 2011 | -$11.90M | – |
| FY2010 | Dec 31, 2010 | -$12.62M | – |
| FY2009 | Dec 31, 2009 | -$9.63M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | -$3.96M | – |
| Q4 FY2021 | Dec 31, 2021 | -$5.75M | – |
| Q3 FY2021 | Sep 30, 2021 | -$3.47M | – |
| Q4 FY2020 | Dec 31, 2020 | -$2.86M | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.99M | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.28M | – |
| Q1 FY2020 | Mar 31, 2020 | -$3.26M | – |
| Q4 FY2019 | Dec 31, 2019 | -$2.29M | – |
| Q3 FY2019 | Sep 30, 2019 | -$2.55M | – |
| Q2 FY2019 | Jun 30, 2019 | -$2.83M | – |
| Q1 FY2019 | Mar 31, 2019 | -$1.47M | – |
| Q4 FY2018 | Dec 31, 2018 | -$2.42M | – |
| Q4 FY2017 | Dec 31, 2017 | -$760.00K | – |
| Q3 FY2017 | Sep 30, 2017 | -$1.90M | – |
| Q2 FY2017 | Jun 30, 2017 | -$2.31M | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.00M | – |
| Q4 FY2016 | Dec 31, 2016 | -$2.10M | – |
| Q3 FY2016 | Sep 30, 2016 | -$2.99M | – |
See a number that looks wrong?